Comparison
3 Methylglutaconic Aciduria Type 5 C1857776 vs 3m Syndrome 3 C3280146
Clinical comparison between 3 Methylglutaconic Aciduria Type 5 and 3M Syndrome 3 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 5 C1857776
A genetic mitochondrial disorder that often causes movement problems, muscle stiffness, and developmental delay. Some forms involve the optic nerve and auditory system. Management focuses on supportive care and addressing specific symptoms.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 5 C1857776
0-5
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 5 C1857776
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 5 C1857776
Chronic
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 5 C1857776
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-5-C1857776 and 3m-syndrome-3-C3280146 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 5 C1857776 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Growth pattern | Growth effects are not the defining supplied feature. | Intrauterine growth restriction and postnatal short stature are described. | High |
| Neurologic movement features | Movement problems, muscle stiffness, and developmental delay are often described. | These neurologic features are not established by the supplied description. | High |
| Facial appearance | Distinctive facial features are not established here. | Distinctive facial features are part of the described phenotype. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 5 C1857776 when
Early childhood neurologic presentation
Movement problems, stiffness, or developmental delay fit the supplied metabolic phenotype.
Moderate
Suspected mitochondrial involvement
Optic-nerve or auditory involvement, when present, supports considering this disorder.
Moderate
Metabolic genetic evaluation
The supplied category is metabolic rather than primarily musculoskeletal.
High
Choose 3m Syndrome 3 C3280146 when
Prenatal growth restriction
Onset is listed as birth or prenatal, with intrauterine growth restriction described.
High
Persistent short stature
Postnatal short stature is a central supplied feature.
High
Musculoskeletal genetic assessment
The condition is categorized as a moderate musculoskeletal genetic disorder.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 5 C1857776 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| Urine organic-acid analysis | May be relevant because the name indicates methylglutaconic aciduria; exact findings are not supplied. | No characteristic organic-acid abnormality is established here. | An abnormal result is not itself a diagnosis and needs specialist confirmation. |
| Growth assessment | No specific growth pattern is established by the source. | Intrauterine restriction and postnatal short stature are expected features. | Serial measurements help characterize 3M syndrome but do not prove its cause. |
| Genetic testing | May support a mitochondrial-disorder diagnosis when clinically indicated. | May support the specific genetic growth syndrome when clinically indicated. | Gene selection and interpretation require a genetics clinician; results are not supplied. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 5 C1857776
- Outcome
- A severe chronic course is described, but individual outcome is not established.
- Factors
- Neurologic, visual, hearing, and developmental involvement may influence function.
3m Syndrome 3 C3280146
- Outcome
- A moderate chronic course centered on growth is described; exact outcome is not established.
- Factors
- Degree of growth restriction, short stature, and associated features may matter.
Time frame: Both are chronic; left onset is early childhood, while right begins prenatally or at birth.
Prognosis requires individualized clinical and genetic assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement problems, stiffness, and developmental delay may occur. Not established as a typical feature in the supplied data. Severity and functional impact vary and are not quantified here. |
| Sensory involvement | Some forms may involve optic nerve or hearing pathways. Sensory complications are not established by the source. Screening decisions should be individualized by clinicians. |
| Growth-related complications | Not a defining supplied complication. Short stature and prenatal growth restriction are central concerns. No treatment dose or outcome rate is established here. |
Patient education highlights
- HighDifferent conditions
These similarly numbered names describe different genetic conditions and should not be used interchangeably.
- HighSupportive care
Management is supportive and symptom-directed; no specific dose or curative treatment is established here.
- MediumSpecialist follow-up
Genetics, neurology, ophthalmology, audiology, or growth specialists may be involved as clinically appropriate.